Creon FDA Approval History
FDA Approved: Yes (First approved April 30, 2009)
Brand name: Creon
Generic name: pancrelipase
Dosage form: Delayed-Release Capsules
Company: Solvay Pharmaceuticals, Inc.
Treatment for: Pancreatic Exocrine Dysfunction
Creon (pancrelipase) is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.
Development timeline for Creon
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.